Saturday 17 October 2026
Export LSTA’s income statement to Excel — free account
Lisata Therapeutics, Inc.
LSTA Healthcare Biotechnology
In the quarter to June 2026, revenue fell 98.3%, EPS grew 40.7% and free cash flow grew 33.0%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
1.03
0.04
−3.74%
Follow LSTA
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | 39.75 | 39.45 | 45.75 | 30.00 | 15.75 | 12.15 | 2.36 | 1.95 | 2.19 | 1.81 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | 199.50 | 116.85 | 174.75 | 81.60 | 54.60 | 73.35 | 17.10 | 4.53 | 3.83 | 4.20 | |||||
| People | |||||||||||||||
| People | Employees | 209 | 22 | 25 | 27 | 24 | 27 | 27 | 25 | 26 | 21 | ||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.01 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | 1 | 0 | ||||
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 100.00 | 100.00 | |||||
| EBT | (31) | (28) | (16) | (19) | (19) | (29) | (57) | (23) | (21) | (18) | |||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (2,078.30) | (10,322.35) | |||||
| Net income | (33) | 22 | (16) | (19) | (8) | (27) | (54) | (21) | (20) | (17) | |||||
| Depreciation | 0 | 1 | 1 | 0 | 0 | 3 | 1 | (1) | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.12 | 0.02 | ||||
| Earnings | (74.81) | 38.38 | (25.04) | (28.19) | (7.95) | (7.50) | (10.47) | (2.58) | (2.40) | (1.91) | |||||
| Cash flow | (54.18) | (34.90) | (30.92) | (27.42) | (8.57) | (6.03) | (4.09) | (2.48) | (2.32) | (1.84) | |||||
| Capex | (2.52) | (0.23) | (0.21) | 0.00 | (0.02) | (0.02) | (0.05) | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | (56.70) | (35.12) | (31.13) | (27.42) | (8.59) | (6.05) | (4.14) | (2.48) | (2.32) | (1.84) | |||||
| Book value | 9.31 | 83.90 | 57.95 | 29.84 | 31.31 | 24.95 | 12.80 | 5.93 | 3.52 | 1.68 | |||||
| Shares, m | 0 | 1 | 1 | 1 | 1 | 4 | 5 | 8 | 8 | 9 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | — | — | — | — | 0.93 | 1.06 | |||||
| P/B | — | — | — | — | — | — | — | — | 0.85 | 1.11 | |||||
| EV/Sales | — | — | — | — | — | — | — | — | (0.12) | 0.22 | |||||
| EV/FCF | — | — | — | — | — | — | — | — | 0.16 | (0.21) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | (24) | (21) | (20) | (19) | (9) | (22) | (21) | (20) | (19) | (16) | ||||
| Capex | (1) | 0 | 0 | — | 0 | 0 | 0 | — | — | 0 | |||||
| Free cash flow | (25) | (21) | (20) | (19) | (9) | (22) | (21) | (20) | (19) | (16) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | 3 | 52 | 38 | 20 | 32 | 92 | 65 | 47 | 29 | 15 | ||||
| Total debt | 6 | 0 | — | 1 | 1 | 1 | 0 | — | — | — | |||||
| Net debt | (1) | (60) | (43) | (25) | (35) | (95) | (69) | (51) | (31) | (16) | |||||
| Shareholders’ equity | 4 | 50 | 37 | 21 | 32 | 92 | 66 | 48 | 29 | 15 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | (58.99) | 39.32 | (29.95) | (53.98) | (25.81) | (41.30) | (63.78) | (32.63) | (44.56) | (62.89) | ||||
| ROIC | (658.43) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | (238.80) | 84.71 | (36.89) | (66.75) | (30.87) | (44.21) | (68.50) | (36.49) | (51.77) | (75.53) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Dec 2025
Charts ten years each
Lisata Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| GDTC CytoMed Therapeutics Limited | $10.3M | — (loss-making) | — (loss-making) | — | n/m | −27.39% (below 0%: shrinking) | 0.00% | — | Compare |
| BLRX BioLineRx Ltd. | $10.2M | — (loss-making) | — (loss-making) | −3.29% (below 0%: shrinking) | n/m | −1,827.71% (below 0%: shrinking) | 79.93% | (1,215.31%) | Compare |
| LTRN Lantern Pharma Inc. | $10.0M | — (loss-making) | — | — | n/m | +25.31% (above 0%: growing) | 0.00% | 0.00% | Compare |
| TOVX Theriva Biologics, Inc. | $9.7M | 0.1× | — | +33.08% (above 0%: growing) | n/m | +34.69% (above 0%: growing) | 100.00% | 0.00% | Compare |
| LSTA Lisata Therapeutics, Inc. | $9.6M | — (loss-making) | — (loss-making) | −98.30% (below 0%: shrinking) | n/m | +33.04% (above 0%: growing) | 100.00% | 0.00% | |
| BIVI BioVie Inc. | $9.6M | — (loss-making) | — | — | n/m | +26.50% (above 0%: growing) | 0.00% | 0.00% | Compare |
| VTGN VistaGen Therapeutics, Inc. | $9.5M | — (loss-making) | — (loss-making) | +504.92% (above 0%: growing) | n/m | +22.23% (above 0%: growing) | 100.00% | (904.34%) | Compare |
| CMMB Chemomab Therapeutics Ltd. Sponsored ADR | $9.4M | — (loss-making) | — | — | n/m | +47.89% (above 0%: growing) | 0.00% | 0.00% | Compare |
| MTVA MetaVia Inc. | $9.0M | — (loss-making) | — | — | n/m | −22.42% (below 0%: shrinking) | — | 0.00% | Compare |
| Median of peers | $9.7M | — | — | +33.08% | — | +23.77% | 0.00% | 0.00% |
Lisata Therapeutics, Inc. (LSTA) key facts
- Concern: Lisata Therapeutics, Inc. reported a net loss of $16.6 million, or a loss of $1.91 per share, for fiscal 2025.
- Lisata Therapeutics, Inc. (LSTA) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, LSTA traded at $1.03, a market capitalization of $9.6 million.
- Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 0.6× sales.
- Return on equity was −75.5% and debt-to-equity 0.00.
- Its Altman Z-score is −43.85 (distress zone) for fiscal 2025.